ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GRAL GRAIL Inc

21.605
1.15 (5.60%)
Last Updated: 15:32:06
Delayed by 15 minutes
Share Name Share Symbol Market Type
GRAIL Inc NASDAQ:GRAL NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.15 5.60% 21.605 21.50 21.65 21.66 20.25 20.27 218,712 15:32:06

GRAIL to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

04/11/2024 9:01pm

PR Newswire (US)


GRAIL (NASDAQ:GRAL)
Historical Stock Chart


From Oct 2024 to Dec 2024

Click Here for more GRAIL Charts.

MENLO PARK, Calif., Nov. 4, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, Nov. 21 at 11:00 a.m. ET

GRAIL, Inc. is a healthcare company whose mission is to detect cancer early when it can be cured. (PRNewsfoto/GRAIL, Inc.)

Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.

About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.
For more information, visit grail.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-present-at-the-canaccord-genuity-medtech-diagnostics-and-digital-health--services-forum-302295742.html

SOURCE GRAIL, Inc.

Copyright 2024 PR Newswire

1 Year GRAIL Chart

1 Year GRAIL Chart

1 Month GRAIL Chart

1 Month GRAIL Chart